Key facts
- This page summarizes Lei Meng's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Sep 2023, 21:56.
Lei Meng - 11 Sep 2023 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)
- Reporting relationship
- Director
- Issuer ticker
- DNTH
- Reported as of
- 11 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Sep 2023, 21:56:23 UTC
- Next SEC filing
- 24 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- MENG LEI, /s/ Adam Veness, as attorney-in-fact for Lei Meng
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Lei Meng filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 13 Sep 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MGTA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +6,500
- Change %
- Price
- $0.000000
- Shares after
- 6,500
- Date
- 11 Sep 2023
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 6,500
- Exercise price
- $11.20
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer.
Footnote F2
Under Ms. Meng's arrangement with Avidity Partners Management LP (the "Avidity"), Ms. Meng holds the option for the benefit of clients of Avidity. Ms. Meng is obligated to turn over to the Avidity any net cash or stock received from the option for the benefit of Avidity. Ms. Meng therefore disclaims beneficial ownership of the option and underlying common stock. The reported shares may be deemed to beneficially owned by (i) Avidity Partners Management LP, (ii) Avidity Partners Management (GP) LLC, the general partner of Avidity Partners Management LP and (iii) each of David Witzke and Michael Gregory, the managing members of Avidity Partners Management (GP) LLC. Under Ms. Meng's arrangement with Avidity Partners Management LP (the "Avidity"), Ms. Meng holds the option for the benefit of clients of Avidity.
Footnote F3
Ms. Meng is obligated to turn over to the Avidity any net cash or stock received from the option for the benefit of Avidity. Ms. Meng therefore disclaims beneficial ownership of the option and underlying common stock. The reported shares may be deemed to beneficially owned by (i) Avidity Partners Management LP, (ii) Avidity Partners Management (GP) LLC, the general partner of Avidity Partners Management LP and (iii) each of David Witzke and Michael Gregory, the managing members of Avidity Partners Management (GP) LLC.
Footnote F4
As of the date hereof, Avidity Partners Management (GP) LLC, David Witzke and Michael Gregory have not yet received the applicable EDGAR codes required to make filings with the Securities and Exchange Commission; however, such Reporting Persons have applied for the applicable codes and will supplement this Form 4 once such codes are available.